Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-049702
Filing Date
2025-05-15
Accepted
2025-05-15 21:01:01
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 11284
  Complete submission text file 0001104659-25-049702.txt   13027
Mailing Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Business Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129 415-489-9980
Redmile Group, LLC (Filed by) CIK: 0001425738 (see all company filings)

EIN.: 208592298 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 18702 N. CREEK PARKWAY SUITE 100 BOTHELL WA 98011
Business Address 18702 N. CREEK PARKWAY SUITE 100 BOTHELL WA 98011 610-321-3700
Immunome Inc. (Subject) CIK: 0001472012 (see all company filings)

EIN.: 770694340 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91961 | Film No.: 25956717
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)